Biogen and Denali Therapeutics announced that BIIB122 (DNL151), a LRRK2 inhibitor, failed to meet primary and secondary endpoints in the Phase 2b LUMA study for early-stage Parkinson's disease. The companies will discontinue development in idiopathic Parkinson's disease, though Denali will continue the Phase 2a BEACON study in LRRK2 variant carriers. The drug demonstrated acceptable safety and >90% kinase inhibition but did not slow disease progression.

Biogen and Denali Therapeutics announced that BIIB122 (DNL151), an investigational LRRK2 inhibitor, failed to meet primary and secondary endpoints in the Phase 2b LUMA study for early-stage Parkinson's disease. The drug did not slow disease progression compared to placebo. Both companies will discontinue development of BIIB122 in idiopathic Parkinson's disease, though Denali will continue the Phase 2a BEACON study in LRRK2 variant carriers with data expected in H1 2027.

The oligonucleotides clinical trial landscape is expanding rapidly with 200+ companies developing 600+ pipeline drugs. Major players like Novartis, Alnylam Pharmaceuticals, Amgen, and WaVe Life Sciences are advancing promising therapies across various clinical stages. Approximately 20+ oligonucleotides are in late-stage development while 150+ are in mid and early stages. Recent developments include SanegeneBio's $110M Series B funding, FDA approvals for multiple orphan drug designations, and several companies advancing Phase II and Phase III trials.

Privium Fund Management acquired 254,857 shares of Denali Therapeutics for approximately $5.07 million in Q1 2026, representing a new 1.02% position in their portfolio. The investment comes after the FDA granted accelerated approval for Denali's first commercial drug, Avlayah, which treats Hunter syndrome and validates their TransportVehicle platform for crossing the blood-brain barrier. While the approval is significant, Denali remains a high-risk biotech bet with $966 million in cash but a $512 million loss in 2025.

Takeda Pharmaceutical has terminated its collaboration with Denali Therapeutics on DNL593, a progranulin replacement therapy for frontotemporal dementia. The decision is strategic and not related to safety or efficacy concerns. Denali regains full ownership and control of the therapy, with plans to report Phase 1/2 trial results by end of 2026. Denali shares fell 3.73% on the news.

The regenerative medicine market, projected to reach $578 billion by 2033, faces a critical manufacturing challenge in scaling cell and gene therapies. Several companies are addressing this bottleneck through different approaches: Prime Medicine with prime editing technology, Madrigal Pharmaceuticals with sustained therapeutic results, Iovance Biotherapeutics with FDA-approved TIL therapy, Denali Therapeutics with protein engineering, and Avaí Bio with a Master Cell Bank for encapsulated cell products that enable off-the-shelf manufacturing.

Denali Therapeutics announced clinical progress across three lysosomal storage disorder programs using its proprietary Enzyme TransportVehicle platform. Tividenofusp alfa (DNL310) for Hunter syndrome showed sustained biomarker reductions and clinical improvements through Week 201, with an FDA PDUFA decision expected April 5, 2026. DNL126 for Sanfilippo syndrome type A demonstrated an 80% mean reduction in cerebrospinal fluid heparan sulfate in preliminary Phase 1/2 data. DNL952 for Pompe disease entered Phase 1 testing with preclinical data showing improved glycogen reduction in muscle and brain.

Denali Therapeutics announced it will present clinical and preclinical data from its Enzyme TransportVehicle (ETV) programs at the 2026 WORLDSymposium in February. The company will showcase continued Phase 1/2 data for tividenofusp alfa (DNL310) for Hunter syndrome, which is under FDA Priority Review with a decision expected by April 5, 2026, as well as preliminary data from DNL126 for Sanfilippo syndrome type A and Phase 1 study design for DNL952 for Pompe disease.

Denali Therapeutics announced publication of Phase 1/2 trial results for tividenofusp alfa (DNL310), an investigational enzyme replacement therapy for Hunter syndrome (MPS II) that crosses the blood-brain barrier. The study showed significant reduction in key disease biomarkers, normalization of heparan sulfate levels in cerebrospinal fluid and urine, and improvements in clinical endpoints including cognition, adaptive behavior, and hearing. The FDA is conducting Priority Review of the Biologics License Application with a decision expected by April 5, 2026.

Denali Therapeutics plans to raise approximately $200 million through a public offering of 9,142,857 common stock shares and pre-funded warrants at $17.50 per share, with underwriters including Goldman Sachs, J.P. Morgan, Morgan Stanley, and Jefferies.

Denali Therapeutics appointed Tim Van Hauwermeiren to its Board of Directors and announced the departure of Chief Medical Officer Carole Ho to Eli Lilly, with Peter Chin assuming the Acting Chief Medical Officer role.

The global Sandhoff disease treatment market is projected to grow from $260 million in 2024 to $456.42 million by 2034, with a 5.75% CAGR. North America dominates the market, and gene therapy is expected to be a key growth segment for treating this rare genetic disorder.